Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.
2021
DOI: 10.1016/j.ijpharm.2020.120053
|View full text |Cite
|
Sign up to set email alerts
|

Paracetamol extended release FDM 3D printlets: Evaluation of formulation variables on printability and drug release

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
15
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 34 publications
(15 citation statements)
references
References 40 publications
0
15
0
Order By: Relevance
“…In this procedure, the drug loaded filament is manufactured by hot melt extrusion to later be fed into the 3D printer and be heated again. For example, Ðuranović et al [26] processed paracetamol loaded filaments based on poly(ε-caprolactone) (PCL) and poly ether oxide (PEO) polymers. They succeeded in extruding filaments and printing with drug loads up to 48% wt at 130 • C but their polymer-drug blends underwent two thermal processes, and although the processing temperature was under the melting point of the paracetamol, their samples showed yellowish discoloration, indicating some degradation or oxidation of the components.…”
Section: Introductionmentioning
confidence: 99%
“…In this procedure, the drug loaded filament is manufactured by hot melt extrusion to later be fed into the 3D printer and be heated again. For example, Ðuranović et al [26] processed paracetamol loaded filaments based on poly(ε-caprolactone) (PCL) and poly ether oxide (PEO) polymers. They succeeded in extruding filaments and printing with drug loads up to 48% wt at 130 • C but their polymer-drug blends underwent two thermal processes, and although the processing temperature was under the melting point of the paracetamol, their samples showed yellowish discoloration, indicating some degradation or oxidation of the components.…”
Section: Introductionmentioning
confidence: 99%
“…Two different approaches can be considered to apply dose personalization: (i) changing the amount of active ingredient in the filament and (ii) modifying the project by changing the dimensions or infill density of the tablet. Although the production of low-dose dosage forms does not cause many difficulties, an increase of the API content is usually associated with a significant decrease in printability; several works reporting the possibility of printing from filaments containing even 50–60% ( w / w ) of the API have been recently published [ 36 , 37 , 38 ]. Sadia et al printed tablets using filaments containing from 2.5% to 50% w / w of hydrochlorothiazide using Eudragit PO with addition of triethyl acetate and tricalcium phosphate.…”
Section: Introductionmentioning
confidence: 99%
“…Among the formulations containing 60% of API, only filament based on PCL and made from PEO 200 K with the addition of Gelucire ® 44/14 were printable. The authors also noted that printing with high drug-loaded filaments is difficult due to the clogging of the printer nozzle [ 37 ]. The 3DP prolonged-release tablets containing theophylline and metformin were reported by Verstraete et al As filament-forming polymers, they used hydrophilic and hydrophobic thermoplastic urethanes containing 20%, 40%, or 60% of API, respectively.…”
Section: Introductionmentioning
confidence: 99%
“…Decision trees are powerful classification algorithms that are used in medicine and other areas [30,[33][34][35]. Decision trees have been also used to analyze the printability of filaments in the FDM technique [36] but there is no literature data on the application of decision tree methodology in SLS printing. Created decision trees can be used for predicting printability instead of usage in a trial-and-error approach, which is both time-and resource-consuming.…”
Section: Decision Treementioning
confidence: 99%